Biologically active 4H-benzo [1,4]oxazin-3-ones

Details Biologically active 4H-benzo [1,4]oxazin-3-ones Biologically active 4H-benzo [1,4]oxazin-3-ones

2001-05-11

2003-04-29

Raymond, Richard L. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S080000, C544S105000

Reexamination Certificate

active

06555536

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to novel 4H-benzo[1,4]oxazin-3-ones useful for the treatment of Non-Insulin Dependant Diabetes Mellitus (NIDDM) and complications thereof and disorders related to lipid metabolism and energy homeostasis such as obesity. More particularly, the compounds act through the peroxisome proliferator activated receptor gamma (PPAR&ggr;). Compounds in the series are PPAR&ggr; modulators.
BACKGROUND OF THE INVENTION
Diabetes is a disease caused by multiple factors and characterized by hyperglycemia which may be associated with increased and premature mortality due to an increased risk for microvascular and macrovascular diseases such as nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovary syndrome (PCOS), hypertension, ischemia, stroke, and heart disease. Type I diabetes (IDDM) results from genetic deficiency of insulin, the hormone regulating glucose metabolism. Type II diabetes is known as non-insulin dependent diabetes mellitus (NIDDM), and is due to a profound resistance to insulin regulatory effect on glucose and lipid metabolism in the main insulin-sensitive tissues, i.e., muscle, liver and adipose tissue. This insulin resistance or reduced insulin sensitivity results in insufficient insulin activation of glucose uptake, oxidation and storage in muscle and inadequate insulin repression of lipolysis in adipose tissue as well as glucose production and secretion in liver. Many Type II diabetics are also obese, and obesity is believed to cause and/or exacerbate many health and social problems such as coronary heart disease, stroke, obstructive sleep apnoea, gout, hyperlipidemia, osteoarthritis, reduced fertility, and impaired psychosocial function.
A class of compounds, thiazolidinediones (glitazones), have been suggested to be capable of ameliorating many symptoms of NIDDM by binding to the peroxisome proliferator activated receptor (PPAR) family of receptors. They increase insulin sensitivity in muscle, liver and adipose tissue in several animal models of NIDDM resulting in correction of the elevated plasma levels of glucose, triglycerides and nonesterified free fatty acids without any occurrence of hypoglycemia. However, undesirable effects have occurred in animal and/or human studies including cardiac hypertrophy, hemadilution and liver toxicity.
Most PPAR&ggr; agonists currently in development have thiazolidinedione ring as their common chemical structure. PPAR&ggr; agonists have been demonstrated to be extremely useful for the treatment of NIDDM and other disorders involving insulin resistance. Recently, troglitazone, rosiglitazone, and pioglitazone have been approved for treatment of type II diabetes. There is also indication that benzimidazole-containing thiazolidinedione derivatives may be used to treat irritable bowel disorder (IBD), inflammation, and cataract (JP 10195057).
JP 09012576 (Yoshitake et al.) discloses benzothiazine derivatives stated as useful therapeutic agents for circulatory system disease and glaucoma.
JP 09012575 (Hiroaki et al.) discloses benzoxazine and benzothiazine derivatives stated to be useful as prophylactic drugs and/or therapeutic drugs in hyperlipemia, hyperglycemia, obesity, diseases attributable to sugar tolerance insufficiency, hypertension, osteoporosis, cachexia, and complications of diabetes such as retinopathy, nephrosis, neuropathy, cataract, coronary artery disease and arteriosclerosis.
WO 99/20614 (Lohray et al.) discloses &bgr;-aryl-&agr;-oxysubstituted alkylcarboxylic acids stated as antiobesity and hypocholesterolemic compounds which may have agonist activity against PPAR&ggr; and/or PPAR&ggr;, and optionally inhibit HMG CoA reductase.
WO 97/17333 (Frechette et al.) and U.S. Pat. Nos. 5,696,117 and 5,854,242 to Frechette et al. disclose benzoxazine and pyrido-oxazine compounds having a moiety of a fused phenyl or fused pyridyl, pharmaceutical compositions containing the compounds, and methods for their production and their use in treating bacterial infections.
U.S. Pat. No. 5,859,051 to Adams et al. discloses the following acetylphenols,
wherein substituents are as described in the reference, which are stated to be useful as antiobesity and antidiabetic compounds without the thiazolidinedione moiety.
WO 99/38845 (De La Brouse-Elwood et al.) discloses the following compounds,
wherein substituents are as described in the reference, which are stated to modulate the PPAR&ggr; receptor and are stated as useful in the diagnosis and treatment of type II diabetes (and complications thereof) and inflammatory disorders.
SUMMARY OF THE INVENTION
The present invention is directed to a compound of Formula I,
or an optical isomer, enantiomer, diastereomer, racemate or racemic mixture thereof, ester, prodrug form, or a pharmaceutically acceptable salt thereof, wherein
A is selected from aryl, heterocyclyl, and C
1
-C
10
alkyl, said aryl, heterocyclyl, and C
1
-C
10
alkyl being optionally substituted with one or more members selected from the group consisting of halogen, OH, aryl, C
3
-C
8
cycloalkyl, C
1
-C
10
alkyl substituted with a halogen, C
1
-C
10
alkyl ether, heterocyclyl, carbonyl, oxime, —C(NNR
3
R
4
)R
1
, —COOR
1
, —CONR
1
R
2
, —OC(O)R
1
, —OC(O)OR
1
, —OC(O)NR
1
R
2
, —NR
1
R
2
, —NR
3
C(O)R
1
, —NR
3
C(O) OR
1
, and —NR
3
C(O)NR
1
R
2
, wherein
R
1
and R
2
are independently selected from hydrogen, C
1
-C
10
alkyl, aryl, heterocyclyl, and alkylaryl, or R
1
and R
2
may be taken together to form a 5- to 10-member ring; and
R
3
and R
4
are independently selected from hydrogen, C
1
-C
10
alkyl, aryl, heterocyclyl, alkylaryl, —C(O)R
1
, or —C(O)NR
1
R
2
;
Z
1
is selected from hydrogen, C
1
-C
6
alkyl, aryl, heterocyclyl, COOR
1
, CONR
1
R
2
, OH, C
1
-C
6
alkyl ether, —OC(O)R
1
, —OC(O)OR
1
, —OC(O)NR
1
R
2
, —NR
1
R
2
, —NR
3
C(O)R
1
, —NR
3
C(O)OR
1
, —NR
3
C(O)NR
1
R
2
, halogen, —C(O)R
1
, —C(NR
3
)R
1
, —C(NOR
3
)R
1
, and —C(NNR
3
R
4
) R
1
;
Z
2
is selected from hydrogen, halogen, C
1
-C
6
alkyl;
Z
1
and Z
2
may together form a fused aromatic ring;
n is an integer from 0 to 3;
G is selected from —COOR
1
, —C(O)COOR
1
, —CONR
1
R
2
, —CF
3
—P(O) (OR
1
) (OR
2
) —S—R
8
,
R
5
and R
6
are independently hydrogen or C
1
-C
6
alkyl;
R
7
is hydrogen, C
1
-C
6
alkyl, or —C(O)R
5
;
R
8
is selected from the group consisting of hydrogen, C
1
-C
6
alkyl, and substituted C
1
-C
6
alkyl; and
B is oxygen or —NR
5
;
E is selected from hydrogen, C
1
-C
6
alkyl and a moiety of the formula
X is hydrogen or oxygen, with the proviso that
when E is hydrogen and G is —COOH, —COOCH
3
, or a moiety of the formula of
A is selected from the group consisting of aryl, heterocyclyl, substituted C
1
-C
6
alkyl and C
7
-C
10
alkyl, provided that when X is hydrogen, n is 1 and G is a moiety of the formula of
A is selected from the group consisting of heterocyclyl, and C
7
-C
10
alkyl.
The compounds of the present invention are PPAR&ggr; modulators useful for the treatment of NIDDM and complications thereof and disorders related to lipid metabolism and energy homeostasis such as obesity.
Illustrative of the invention is a pharmaceutical composition comprising a pharmaceutically acceptable carrier and any of the compounds described above. Illustrating the invention is a pharmaceutical composition made by mixing any of the compounds described above and a pharmaceutically acceptable carrier. An illustration of the invention is a process for making a pharmaceutical composition comprising mixing any of the compounds described above and a pharmaceutically acceptable carrier.
An embodiment of the invention is a method of treating a subject suffering from a disorder in glucose and lipid metabolism, which comprises administering to the subject a therapeutically effective amount of a compound of Formula I.
Another embodiment of the invention is a method of inhibiting the onset of a condition of a disorder in glucose and lipid metabolism, which comprises administering to the subject a prophylactically effective dose of a compound of Formula I.
Further illustrating t

Affiliated with

Also associated with

Rating

Biologically active 4H-benzo [1,4]oxazin-3-ones does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Biologically active 4H-benzo [1,4]oxazin-3-ones, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biologically active 4H-benzo [1,4]oxazin-3-ones will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3097322